Drug Profile
Lercanidipine modified release
Alternative Names: Lercanidipine MRLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Recordati
- Developer Allergan
- Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 19 Jan 2022 Osmotica Pharmaceuticals is now called RVL Pharmaceuticals
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals